By Katherine Hamilton
Recognify Life Sciences, a company Atai Life Sciences is a strategic investor in, said its trial for a cognitive decline treatment missed its primary endpoint. Atai shares fell 13% to $3.08 in after-hours trading Friday.
Amrep logged lower revenue in its latest fiscal year. The stock fell 6% to $22.21 after the bell.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
July 25, 2025 18:23 ET (22:23 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.